



Convegno annuale LIRH ONLUS

LA RICERCA
sulle malattie rare e
LE PROSPETTIVE
di cura per la malattia di
HUNTINGTON

Roma, sabato 2 Dicembre, 2017

*Ore 9:30-16:00 Sala Loyola - Roma Eventi
Piazza della Pilotta 4 (Fontana di Trevi)*

L'impegno di Teva nella ricerca sulla malattia di Huntington

Antonella Veneziano

Global Medical Director

Roma, 2 dicembre 2017

Le nostre Aree Terapeutiche



Emicrania



SM, disordini del
movimento e
neurodegenerazione



Oncologia e
dolore



Respiratorio

Il Programma di Ricerca sulla malattia di Huntington:

Laquinimod (pHII)
Pridopidine (pHIII)

Disponibile negli Stati Uniti:


The logo for Austedo (deutetrabenazine) features a stylized blue and grey icon to the left of the brand name 'Austedo' in a bold, purple, sans-serif font. Below the brand name, '(deutetrabenazine)' is written in a smaller, grey, sans-serif font, followed by '6 mg, 9 mg, and 12 mg tablets' in an even smaller, grey, sans-serif font.

Austedo[™]
(deutetrabenazine)
6 mg, 9 mg, and 12 mg tablets

Laquinimod: **immunomodulatory** treatment for HD

**Modulate
microglial &
astrocytic
activation**

**inflammatory
cytokines**



**NF-κB
activation**



**BDNF
Levels**



BDNF = brain derived neurotrophic factor,
NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells
Ellrichmann G, et al. *Clin Dev Immunol.* 2013;2013:1-11.



Trial Population, Treatment and Outcomes

Population and Treatment

Participants

- Symptomatic HD ages 21-55 y
- 36-49 CAG repeats
- UHDRS-TMS > 5
- UHDRS-TFC ≥ 8

Treatment Arms

OF PATIENTS

Screening	Laq 0.5 mg qd	100
	Laq 1.0 mg qd	100
	(Laq 1.5 mg qd	100 discontinued)
	Placebo	100

Outcome Measures

Efficacy

- **Primary Endpoint:** Δ UHDRS-TMS @ week 52

Secondary Endpoints:

- Δ HD-CAB
- Δ TFC
- Δ CIBIC-Plus global score
- Δ % caudate volume MRI

Exploratory Endpoints

- Δ MRI volume whole brain, ventricles & white-matter
- Δ UHDRS-FA
- Δ Q-Motor


Sub-studies

- Patient genetic profiles for clinical response to treatment
- PET-study: Microglia Activation
- Monocyte gene expression for laquinimod effects on HD pathology
- MRS assessment of neuronal integrity and astrocytosis
- Peripheral cytokine and proteomic analysis in response to treatment

Timeline



Pridopidina: meccanismo d'azione




PRIDE-HD study design

A Phase 2 study in HD patients




The Pride-HD Study
EMBRACING CHALLENGES




Open PRIDE-HD

The present clinical study is planned as an open-label extension of PRIDE-HD study, in order to collect and assess long term data on the safety, tolerability, and efficacy of Pridopidine in patients with Huntington's disease (HD).



La tecnologia a supporto dei prossimi trial clinici



Lo sviluppo di pridopidina guidato dai bisogni dei pazienti

- Come emerso da un'intervista ai pazienti e ai caregiver, condotta a Settembre del 2015 dall'FDA, in preparazione ad un incontro focalizzato sullo sviluppo di nuovi farmaci, un trattamento che possa ritardare il declino funzionale, potrebbe avere un profondo impatto sulla vita dei pazienti.
- I risultati dello studio PRIDE-HD suggeriscono che il trattamento con pridopidina nei pazienti HD nella fase iniziale, possa avere un impatto positivo sulla Total Functional Capacity (TFC).
- L' HD-Cope si è fatta portavoce con l'FDA della necessità di iniziare immediatamente studi clinici con la TFC come endpoint primario.
- Teva sta lavorando con FDA, EMA e Associazioni Pazienti per disegnare e implementare lo studio di fase III.

UHDRS Total Functional Capacity is the most widely accepted tool for assessing disease progression in HD

VI. FUNCTIONAL CAPACITY

70. OCCUPATION

- 0 = unable
- 1 = marginal work only
- 2 = reduced capacity for usual job
- 3 = normal

71. FINANCES

- 0 = unable
- 1 = major assistance
- 2 = slight assistance
- 3 = normal

72. DOMESTIC CHORES

- 0 = unable
- 1 = impaired
- 2 = normal

73. ADL


- 0 = total care
- 1 = gross tasks only
- 2 = minimal impairment
- 3 = normal

74. CARE LEVEL

- 0 = full time skilled nursing
- 1 = home or chronic care
- 2 = home

- A well established endpoint for trials aiming to slow rate of functional decline
- Range: 0-13
- Floor and ceiling effects make this more sensitive to change in early HD, than late HD

La nostra priorità è trattare tutti i bisogni dei pazienti



Grazie!
